Clinical Core

核心B：临床核心摘要/摘要： 阿尔茨海默病的诊断、治疗和预防的进展在很大程度上取决于 从正常状态过渡到临床前阶段的大型“可供试验”参与者队列的可用性 AD阶段，轻度认知障碍(MCI)，到早期AD。PIT-ADRC临床核心已经有效地 实现了这一点，自成立以来评估了4700多名参与者，并提供了 参与者、生物样本和广泛研究的数据，这些研究严重依赖于不同的临床 人群：有AD风险的参与者(例如，预防、生物标记物研究)；临床AD的参与者(例如 阿尔茨海默病患者(阿尔茨海默病患者，精神病患者)；尸检证实的阿尔茨海默病患者(例如，尸检组织研究)； 以及患有其他痴呆症的参与者(例如DLB财团)。临床核心已经开发出方法来 最大限度地提高灵活性，以满足这些不同的、不断变化的、得到支持的调查的需求。在……里面 除了作为PIT-ADRC许多资助研究的关键资源之外，临床核心还将提供 将作为神经成像核心和Biomarker评估生物标记物的焦点的参与者 和神经遗传学核心。在此期间，我们还保持了我们强大的 所有参与者的神经精神特征，并进一步提高了我们的尸检同意率，支持 神经病理核心和多个附属R01。我们延续了我们提供服务的强劲记录 每年大量参与者的遗传样本和数据，供地方R01和国家和 国际财团。最后，我们增加了具有帕金森氏症专业知识的新研究人员 综合症和FTLD，并制定了新的程序，以提高完成的后续访问的比率 我们的参与者。这些成就已经为临床核心做好了准备，以保持其在 以下一套拟议的具体目标：1)在研究开始时和在年度后续行动中进行评价 参加PIT-ADRC的正常对照组、MCI前期、MCI、AD和相关痴呆症参与者；2)至 确保最大限度地参与临床、干预、脑成像、生物标记物和尸检研究 在纵向随访期间提供适当的研究转介和临床服务；3)提供 临床数据、研究参与者、DNA样本以及技术和科学领导力，以支持新的和 匹兹堡大学内外皮特-亚洲发展研究中心正在进行的研究项目，并支持 国家联合体研究；4)与外联、征聘和参与核心协作，以 促进招募和留住不同的参与者；5)支持研究和教育 培训下一代痴呆症研究人员的组成部分，提供研究参与者、样本、 和数据。

Core B: Clinical Core Summary/Abstract: Progress in the diagnosis, treatment, and prevention of Alzheimer’s Disease (AD) depends critically on the availability of large “trial-ready” cohorts of participants spanning the transition from normal through preclinical AD stages, mild cognitive impairment (MCI), to early AD. The PITT-ADRC Clinical Core has effectively accomplished this, evaluating a cohort of more than 4700 participants since its inception and providing participants, biologic samples, and data for a wide array of studies that depend critically on differing clinical populations: participants at risk for AD (e.g. prevention, biomarker studies); participants with clinical AD (e.g. GWAS of AD, GWAS of psychosis); participants with autopsy-confirmed AD (e.g. postmortem-tissue studies); and participants with other dementias (e.g. DLB consortium). The Clinical Core has developed approaches to maximize flexibility in meeting the needs of these diverse, and evolving, set of supported investigations. In addition to its role as a critical resource for many funded studies in the PITT-ADRC, the Clinical Core will provide participants that will serve as a focus for biomarker evaluation by the Neuroimaging Core and the Biomarker and Neurogenetics Core. During the current period we have also maintained our strong history of neuropsychiatric characterization of all participants and further enhanced our rate of autopsy consent, supporting the Neuropathology Core and multiple affiliated R01s. We have continued our strong record of providing genetic samples and data on large numbers of participants annually for use in local R01s and in national and international consortia. Finally, we have added new investigators with specialized expertise in Parkinsonian syndromes and FTLD and have developed new procedures to increase the rate of completed follow-up visits for our participants. These accomplishments have prepared the Clinical Core to maintain its productivity in the following set of proposed Specific Aims: 1) To perform evaluations at study entry and at annual follow-up of Normal Control, pre-MCI, MCI, AD, and related dementia participants participating in the PITT-ADRC; 2) To assure maximum participation in clinical, intervention, brain imaging, biomarker, and autopsy studies by providing appropriate research study referrals and clinical services during longitudinal follow-up; 3) To provide clinical data, research participants, DNA samples, and technical and scientific leadership to support new and ongoing research projects at the PITT-ADRC, within and outside the University of Pittsburgh, and to support national consortium studies; 4) In collaboration with the Outreach, Recruitment, and Engagement Core, to facilitate recruitment and retention of diverse participants; 5) To support the Research and Education Component in training the next generation of dementia researchers by providing research participants, samples, and data.